Achieve Life Sciences, Inc. (ACHV)
NASDAQ: ACHV · Real-Time Price · USD
4.305
-0.035 (-0.81%)
Nov 20, 2024, 4:00 PM EST - Market closed
Company Description
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction.
The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
Achieve Life Sciences, Inc.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Richard A. Stewart |
Contact Details
Address: 1040 West Georgia Street, Suite 1030 Vancouver, BC V6E 4H1 Canada | |
| Phone | 604-210-2217 |
| Website | achievelifesciences.com |
Stock Details
| Ticker Symbol | ACHV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000949858 |
| CUSIP Number | 004468203 |
| ISIN Number | US0044685008 |
| Employer ID | 95-4343413 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Richard A. B. Stewart | Chief Executive Officer and Executive Director |
| Thomas B. King M.B.A. | Executive Chairman |
| Dr. Cindy Jacobs M.D., Ph.D. | President, Chief Medical Officer and Director |
| Jerry Wan | Principal Accounting Officer |
| Dr. Anthony Clarke Ph.D. | Chief Scientific Officer |
| Jaime Xinos | Chief Commercial Officer |
| Dr. Mark L. Rubinstein | Head of Medical Affairs |
| Craig Donnelly | Executive Vice President of CMC and Regulatory CMC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | EFFECT | Notice of Effectiveness |
| Nov 14, 2024 | EFFECT | Notice of Effectiveness |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 7, 2024 | POS AM | Post-Effective amendments for registration statement |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 4, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 31, 2024 | SCHEDULE 13G/A | Filing |
| Oct 31, 2024 | SCHEDULE 13G/A | Filing |